Moderna could get explosive above $200 as anyone who shorted last week's valuation downgrade has to cover. The shakeout on that downgrade was a killer opportunity, and the stock is now back over $200. x.com 

Moderna looks like a logical play on plague-outbreak concerns, though this is outside areas of expertise. A Russian lab worker's sudden death has raised fears of a plague crisis, per Zero Hedge, with the Trump team monitoring the outbreak, and the stock is acting well. x.com 

Moderna's approaching October 24 data release at a Madrid conference makes some pre-event profit-taking likely. After the release, the stock could be $400, $200 or $40; the outcome is unknown. x.com 

Moderna is extremely attractive because curing cancer is a big story, but more consolidation is likely first. The weekly chart shows a wide gap between price and the upper Bollinger Band, so volatility may need another week or two to ebb before the stock possibly starts moving higher. x.com 

Moderna looks likely to stay relatively stable above its gap-up price into next year, as big buyers return. A $6M sale of March 2027 $110 puts bets on exactly that, which seems logical. Yesterday's $30B was the second-largest dollar buy volume ever for the stock, after buy volumes had already re-emerged; January's buying, the largest since Q2 2024, came when the stock was above $100, versus about $50 now. x.com  x.com 

Moderna's data catalyst is done, and it won't get an early stop in RCC. That makes it a good short here, with the story over until at least next summer. x.com 

Moderna's cancer-cure mystery and optimism are the conditions that drive big stock moves. Its theme is now hot to trade, alongside related stocks. CoreWeave's 2025 AI data-center IPO rode similar uncertainty about AI revenue while AI was hot; it now faces AI-spending worries. x.com 

Moderna's next push is cancer vaccines after its COVID-19 run. The stock is about to enter a re-accumulation stage, a chance to buy heavily before another huge move, and a single article could send it higher. x.com 

Moderna looks slightly vulnerable after tripling in two weeks without follow-up news. A wedge pattern is forming with lower highs. If it holds $140, buyers could step in and drive another bounce back to $150+. x.com 

Moderna could re-rate toward $210 by the end of 2027 because the market should move ahead of its free cash flow inflection. That assumes free cash flow reaches breakeven by mid-2028, driven by successful commercialization of its personalized mRNA cancer therapy. x.com